Nuclear Medicine Diagnostics Market, Size, Share Trends, Growth Opportunities and Competitive Outlook

sols barter

posted on 3 weeks ago — updated on 1 second ago

28
views

Data Bridge Market Research analyses that the nuclear medicine diagnostics market which was USD 5.90 billion in 2021, would rocket up to USD 13.21 billion by 2029, and is expected to undergo a CAGR of 10.60% during the forecast period 2022 to 2029.

"Global Nuclear Medicine Diagnostics Market - Overview, Size, Share, Industry Trends and Opportunities

Global Nuclear Medicine Diagnostics Market, By Type (SPECT Radiopharmaceuticals, PET Radiopharmaceuticals), Application (SPECT Applications, PET Applications), Procedure (Central Nervous System, Endocrine, Skeletal, Gastrointestinal, Genito-urinary, Pulmonary), End User (Hospitals and diagnostic centers, Research Institutes) – Industry Trends and Forecast to 2029.

Access Full 350 Pages PDF Report @

https://www.databridgemarketresearch.com/reports/global-nuclear-medicine-diagnostics-market

**Segments**

- By Type (Diagnostic, Therapeutic)
- By Procedure (SPECT, PET)
- By Application (Oncology, Cardiology, Neurology, Others)

Nuclear medicine diagnostics market is segmented based on type, procedure, and application. In terms of type, the market is categorized into diagnostic and therapeutic segments. The diagnostic segment is expected to dominate the market as nuclear medicine plays a crucial role in the diagnosis of various diseases. On the other hand, the therapeutic segment is also witnessing growth due to the increasing adoption of nuclear medicine for treatment purposes. When it comes to procedures, the market is divided into Single-Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET). Both SPECT and PET procedures are widely used for nuclear imaging and play a significant role in diagnosing and monitoring diseases. Lastly, based on application, the market is segmented into oncology, cardiology, neurology, and other areas. The oncology segment holds a significant market share due to the rising prevalence of cancer worldwide. However, the cardiology and neurology segments are also growing steadily due to the increasing use of nuclear medicine in diagnosing heart and brain-related disorders.

**Market Players**

- Siemens Healthcare GmbH
- GE Healthcare
- Cardinal Health
- Novartis AG
- Bayer AG
- Lantheus Medical Imaging, Inc.
- Bracco Imaging S.p.A.
- Nordion (Canada) Inc.
- Eczacıbaşı-Monrol Nuclear Products
- NTP Radioisotopes SOC Ltd.

Key players in the global nuclear medicine diagnostics market include Siemens Healthcare GmbH, GE Healthcare, Cardinal Health, Novartis AG, Bayer AG, Lantheus Medical Imaging, Inc., Bracco Imaging S.p.A., Nordion (Canada) Inc., Eczacıbaşı-Monrol Nuclear Products, and NTP Radioisotopes SOC Ltd. These companies are focusing on strategies suchThe global nuclear medicine diagnostics market is witnessing significant growth, driven by the increasing prevalence of various diseases, technological advancements in imaging techniques, and the rising demand for accurate diagnostic tools. Key market players such as Siemens Healthcare GmbH, GE Healthcare, and Cardinal Health are continuously focusing on developing innovative nuclear medicine solutions to cater to the evolving needs of healthcare providers and patients worldwide. These companies are investing heavily in research and development activities to introduce advanced diagnostic and therapeutic products that offer improved imaging accuracy, reduced radiation exposure, and enhanced patient comfort.

Siemens Healthcare GmbH is a prominent player in the nuclear medicine diagnostics market, offering a wide range of imaging systems, radiopharmaceuticals, and software solutions. The company's cutting-edge PET/CT and SPECT/CT systems provide clinicians with valuable insights for the early detection and treatment monitoring of various diseases. GE Healthcare is another key player known for its comprehensive portfolio of nuclear medicine devices and radiopharmaceuticals. GE Healthcare's innovative imaging solutions, including PET/MR and SPECT/CT machines, enable precise disease diagnosis and personalized treatment planning.

Cardinal Health is a leading provider of radiopharmaceutical products and nuclear medicine services, offering solutions for both diagnostic and therapeutic applications. The company's state-of-the-art production facilities and distribution network ensure the timely supply of high-quality radiopharmaceuticals to healthcare facilities worldwide. Novartis AG and Bayer AG are pharmaceutical giants actively involved in the nuclear medicine diagnostics market, focusing on the development of novel radiotracers and targeted therapies for various diseases. These companies are leveraging their expertise in drug discovery and development to create innovative solutions that improve patient outcomes and drive market growth.

Lantheus Medical Imaging, Inc., Bracco Imaging S.p.A., Nordion (Canada) Inc., Eczacıbaşı-Monrol Nuclear Products, and NTP Radioisotopes SOC Ltd. are also key players contributing to the expansion of the global nuclear medicine diagnostics market. These companies specialize in the manufacturing and**Global Nuclear Medicine Diagnostics Market, By Type (SPECT Radiopharmaceuticals, PET Radiopharmaceuticals), Application (SPECT Applications, PET Applications), Procedure (Central Nervous System, Endocrine, Skeletal, Gastrointestinal, Genito-urinary, Pulmonary), End User (Hospitals and diagnostic centers, Research Institutes) – Industry Trends and Forecast to 2029.**

The global nuclear medicine diagnostics market is poised for significant growth, driven by factors such as the increasing prevalence of various diseases, technological advancements in imaging techniques, and the growing demand for accurate diagnostic tools. The market is segmented by type into SPECT Radiopharmaceuticals and PET Radiopharmaceuticals, each playing a crucial role in nuclear imaging for diagnostic and therapeutic purposes. The application segment encompasses SPECT Applications and PET Applications, highlighting the diverse uses of nuclear medicine in oncology, cardiology, neurology, and other medical fields. Procedures such as Central Nervous System imaging, Endocrine scans, Skeletal examinations, Gastrointestinal studies, Genito-urinary evaluations, and Pulmonary assessments further emphasize the wide-ranging applications of nuclear medicine in healthcare.

Key players in the market, including Siemens Healthcare GmbH, GE Healthcare, and Cardinal Health, are at the forefront of innovation, developing advanced imaging solutions and radiopharmaceutical products to address the evolving healthcare needs worldwide. Siemens Healthcare GmbH offers cutting-edge PET/CT and SPECT/CT systems for early

TABLE OF CONTENTS

Part 01: Executive Summary

Part 02: Scope of the Report

Part 03: Research Methodology

Part 04: Market Landscape

Part 05: Pipeline Analysis

Part 06: Market Sizing

Part 07: Five Forces Analysis

Part 08: Market Segmentation

Part 09: Customer Landscape

Part 10: Regional Landscape

Part 11: Decision Framework

Part 12: Drivers and Challenges

Part 13: Market Trends

Part 14: Vendor Landscape

Part 15: Vendor Analysis

Part 16: Appendix

Core Objective of Nuclear Medicine Diagnostics Market:

Every firm in the Nuclear Medicine Diagnostics Market has objectives but this market research report focus on the crucial objectives, so you can analysis about competition, future market, new products, and informative data that can raise your sales volume exponentially.

Size of the Nuclear Medicine Diagnostics Market and growth rate factors.
Important changes in the future Nuclear Medicine Diagnostics Market.
Top worldwide competitors of the Market.
Scope and product outlook of Nuclear Medicine Diagnostics Market.
Developing regions with potential growth in the future.
Tough Challenges and risk faced in Market.
Global Nuclear Medicine Diagnostics top manufacturers profile and sales statistics.

Browse Trending Reports:

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC : +653 1251 975

Email: corporatesales@databridgemarketresearch.com"